Pursuant to its July-Aug 2022 audit of Jubilant Generics Ltd s Solid Dosage Manufacturing facility at Roorkee it has determined inspection classification of the facility as official action indicated .
Visiongain has launched a new report on Global Biopharmaceuticals Contract Manufacturing Market Forecast 2022-2032: - Market Segment by Source (Mammalian,.
While the term loan and bonds aggregate to $350 million, about Rs 2,787 crore, the company is raising another tranche of $50 million (about Rs 400 crore) for capital expenditure.